Insulin resistance and steatosis in humans.
暂无分享,去创建一个
[1] Claudio Cobelli,et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men , 2006, Proceedings of the National Academy of Sciences.
[2] L. J. Hardies,et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. , 2004, The Journal of clinical endocrinology and metabolism.
[3] K. Petersen,et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. , 2002, The Journal of clinical investigation.
[4] J. Olefsky,et al. Inflammation and insulin resistance , 2008, FEBS letters.
[5] J. Jessurun,et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.
[6] A. Häkkinen,et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. , 2005, Journal of Clinical Endocrinology and Metabolism.
[7] T. Funahashi,et al. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. , 2003, The Journal of clinical endocrinology and metabolism.
[8] H. Ginsberg,et al. Regulation of plasma triglycerides in insulin resistance and diabetes. , 2005, Archives of medical research.
[9] S. Kahn,et al. Review: The role of insulin resistance in nonalcoholic fatty liver disease. , 2006, The Journal of clinical endocrinology and metabolism.
[10] L. N. Valenti,et al. Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis , 2007, Diabetes.
[11] J. Maher,et al. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis , 2008, Hepatology.
[12] J. Kench,et al. Beyond insulin resistance in NASH: TNF‐α or adiponectin? , 2004, Hepatology.
[13] K. Petersen,et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. , 2005, Diabetes.
[14] S. Kaneko,et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. , 2007, Gastroenterology.
[15] H. Yki-Järvinen. Fat in the liver and insulin resistance , 2005, Annals of medicine.
[16] Jacqueline Capeau,et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. , 2006, European cytokine network.
[17] Donald D Hensrud,et al. Splanchnic lipolysis in human obesity. , 2004, The Journal of clinical investigation.
[18] J. Crespo,et al. Gene expression of tumor necrosis factor α and TNF‐receptors, p55 and p75, in nonalcoholic steatohepatitis patients , 2001 .
[19] A. Häkkinen,et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. , 2004, Diabetes.
[20] Laura Herrero,et al. Obesity, inflammation, and insulin resistance. , 2007, Gastroenterology.
[21] J. Flier,et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.
[22] J. Clore,et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.
[23] J. Capeau,et al. Les syndromes lipodystrophiques : des adipopathies congénitales ou acquises , 2006 .
[24] C. Ji. Dissection of endoplasmic reticulum stress signaling in alcoholic and non‐alcoholic liver injury , 2008, Journal of Gastroenterology and Hepatology.
[25] Philippe Giral,et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. , 2008, Gastroenterology.
[26] K. Petersen,et al. Etiology of insulin resistance. , 2006, The American journal of medicine.
[27] K. Petersen,et al. Disordered lipid metabolism and the pathogenesis of insulin resistance. , 2007, Physiological reviews.
[28] F. Foufelle,et al. SREBP-1c Transcription Factor and Lipid Homeostasis: Clinical Perspective , 2007, Hormone Research in Paediatrics.
[29] M. Tsutsumi,et al. Usefulness of a Combined Evaluation of the Serum Adiponectin Level, HOMA-IR, and Serum Type IV Collagen 7S Level to Predict the Early Stage of Nonalcoholic Steatohepatitis , 2007, The American Journal of Gastroenterology.
[30] C. Kahn,et al. Critical nodes in signalling pathways: insights into insulin action , 2006, Nature Reviews Molecular Cell Biology.
[31] I. Leclercq,et al. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. , 2007, Journal of hepatology.
[32] E. Ferrannini,et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms , 2005, Diabetologia.
[33] K. Pietiläinen,et al. Liver fat in the metabolic syndrome. , 2007, The Journal of clinical endocrinology and metabolism.
[34] D. Accili,et al. The double life of Irs. , 2008, Cell metabolism.
[35] R. DePinho,et al. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. , 2008, Cell metabolism.
[36] G. Musso,et al. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH , 2008, Hepatology.
[37] T. Noda,et al. Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. , 2008, Cell metabolism.
[38] Y. Le Marchand-Brustel,et al. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. , 2005, Biochimie.
[39] D. Pessayre. Role of mitochondria in non‐alcoholic fatty liver disease , 2007, Journal of gastroenterology and hepatology.